Literature DB >> 21609231

Surgical treatment of age-related macular degeneration.

Ayham R Skaf1, Tahmer Mahmoud.   

Abstract

Choroidal neovascularization (CNV) and geographic atrophy (GA) are serious and potentially devastating complications of age-related macular degeneration (AMD), a leading cause of blindness in the developed world. While anti-vascular endothelial growth factor (VEGF) therapies have emerged as the current standard treatment of choice for choroidal neovascularization, the requirement for indefinite injections places a tremendous burden on physicians and patients, and may have disappointing outcomes in hemorrhagic neovascular AMD. No superior agents exist to treat large subretinal hemorrhage and geographic atrophy. Over the years, several vitreoretinal surgical approaches have been developed to treat macular degeneration, and these surgical options may still play a role in the management of specific complications of AMD. This review summarizes the principles, techniques, and results of surgical treatments for neovascular and non-neovascular age-related macular degeneration, with emphasis on submacular surgery for removal of CNV, full and limited macular translocation, retinal pigment epithelium, and choroid transplants as well as treatment of thick subretinal hemorrhage.

Entities:  

Mesh:

Year:  2011        PMID: 21609231     DOI: 10.3109/08820538.2011.577133

Source DB:  PubMed          Journal:  Semin Ophthalmol        ISSN: 0882-0538            Impact factor:   1.975


  5 in total

1.  Magnetic nanoparticles conjugated with "RPE cell -MCP-1 antibody -VEGF antibody" compounds for the targeted therapy of age-related macular degeneration: a hypothesis.

Authors:  Zhao-Jiang Du; Peng Li; Li Wang
Journal:  Int J Ophthalmol       Date:  2017-05-18       Impact factor: 1.779

2.  Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT).

Authors:  Michael M Altaweel; Ebenezer Daniel; Daniel F Martin; Robert A Mittra; Juan E Grunwald; Michael M Lai; Alexander Melamud; Lawrence S Morse; Jiayan Huang; Frederick L Ferris; Stuart L Fine; Maureen G Maguire
Journal:  Ophthalmology       Date:  2014-10-11       Impact factor: 12.079

Review 3.  Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases.

Authors:  Raafay Sophie; Abeer Akhtar; Yasir J Sepah; Mohamed Ibrahim; Millena Bittencourt; Diana V Do; Quan Dong Nguyen
Journal:  Biol Ther       Date:  2012-05-29

4.  FPR1 interacts with CFH, HTRA1 and smoking in exudative age-related macular degeneration and polypoidal choroidal vasculopathy.

Authors:  X Y Liang; L J Chen; T K Ng; J Tuo; J-L Gao; P O S Tam; T Y Y Lai; C-C Chan; C P Pang
Journal:  Eye (Lond)       Date:  2014-10-03       Impact factor: 3.775

5.  Commentary: Retinal pigment epithelium-choroid patch graft for large submacular hemorrhage.

Authors:  Dhanashree Ratra
Journal:  Indian J Ophthalmol       Date:  2020-10       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.